oral MPO covalent inhibitor

Ph. IIb/III candidate in HFpEF

previous literature and selectivity opt

J. Med. Chem.

AstraZeneca, Gothenburg, SE

AZD4831 chemical structure oral MPO covalent inhibitor - AstraZeneca, Gothenburg, SE

Context. AZD4831 (AstraZeneca) is an oral covalent myeloperoxidase (MPO) inhibitor being developed for heart failure. Almost half of chronic heart disease patients suffer from heart failure with a preserved…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: